These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32407047)

  • 1. Post-heart transplantation lymphoproliferative diseases (PTLDs) and the diagnostic role of [18f] FDG-PET/CT.
    Sica A; DE Rimini ML; Sagnelli C; Casale B; Spada A; Reginelli A; Amarelli C; Maiello C; Belfiore MP; Creta M; Ciccozzi M; Sagnelli E; Troiani T; Cappabianca S
    Minerva Med; 2021 Jun; 112(3):338-345. PubMed ID: 32407047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease.
    Bianchi E; Pascual M; Nicod M; Delaloye AB; Duchosal MA
    Transplantation; 2008 Mar; 85(5):707-12. PubMed ID: 18337664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring.
    von Falck C; Maecker B; Schirg E; Boerner AR; Knapp WH; Klein C; Galanski M
    Eur J Radiol; 2007 Sep; 63(3):427-35. PubMed ID: 17293073
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Montes de Jesus FM; Glaudemans AWJM; Tissing WJ; Dierckx RAJO; Rosati S; Diepstra A; Noordzij W; Kwee TC
    J Nucl Med; 2020 Sep; 61(9):1307-1313. PubMed ID: 32005775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.
    Montes de Jesus FM; Kwee TC; Kahle XU; Nijland M; van Meerten T; Huls G; Dierckx RAJO; Rosati S; Diepstra A; van der Bij W; Verschuuren EAM; Glaudemans AWJM; Noordzij W
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):529-536. PubMed ID: 31444510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis.
    Vali R; Punnett A; Bajno L; Moineddin R; Shammas A
    Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
    Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of F-18-Fluoro-2-Deoxy-Glucose PET/Computed Tomography Scans in the Management of Post-Transplant Lymphoproliferative Disease in Pediatric Patient.
    Xu YF; Yang JG
    PET Clin; 2020 Jul; 15(3):309-319. PubMed ID: 32498987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder.
    Panagiotidis E; Quigley AM; Pencharz D; Ardeshna K; Syed R; Sajjan R; Bomanji J
    Leuk Lymphoma; 2014 Mar; 55(3):515-9. PubMed ID: 23772644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder.
    Takehana CS; Twist CJ; Mosci C; Quon A; Mittra E; Iagaru A
    Nucl Med Commun; 2014 Mar; 35(3):276-81. PubMed ID: 24296883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children.
    Wang SS; Mechinaud F; Thursky K; Cain T; Lau E; Haeusler GM
    J Paediatr Child Health; 2018 May; 54(5):487-492. PubMed ID: 29235187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
    Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O
    Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.
    Wareham NE; Lundgren JD; Da Cunha-Bang C; Gustafsson F; Iversen M; Johannesen HH; Kjær A; Rasmussen A; Sengeløv H; Sørensen SS; Fischer BM
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):421-431. PubMed ID: 27838763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of bone marrow involvement in newly diagnosed post-transplant lymphoproliferative disorder: (18)F-fluorodeoxyglucose positron emission tomography/computed tomography versus bone marrow biopsy.
    Gheysens O; Thielemans S; Morscio J; Boeckx N; Goffin KE; Deroose CM; Sagaert X; Wlodarska I; Verhoef G; Dierickx D; Tousseyn T
    Leuk Lymphoma; 2016 Oct; 57(10):2382-8. PubMed ID: 26854937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.